|1|Distinct driver mutation profiles of childhood and adolescent essential thrombocythemia. (25132652)
Langabeer S.E.... McMahon C.
|2|Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia. (25332611)
Qin Y.W.... Wang C.
|3|Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. (25037629)
Tefferi A.... Vannucchi A.M.
|4|Phase III, single-arm study investigating the efficacy, safety, and tolerability of anagrelide as a second-line treatment in high-risk Japanese patients with essential thrombocythemia. (25160063)
Kanakura Y.... Okamoto S.
|5|Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France. (24118452)
Rey J.... Kiladjian J.J.
|6|The therapeutic goals of essential thrombocythemia under the clouds of over-treatment and under-treatment. (23647225)
|7|Combination therapy of hydroxycarbamide with anagrelide inpatients with essential thrombocythemia in the evaluation ofXagrid(R): efficacy and long-term safety study. (24334294)
Gugliotta L.... BirgegAYrd G.
|8|The relationship of the active and latent forms of TGF-I^1 with marrow fibrosis in essential thrombocythemia and primary myelofibrosis. (22200991)
Ponce C.C.... Silva M.R.
|9|Bilateral vertebral artery dissection and essential thrombocythemia with JAK2 mutation. (22677324)
Verdure P.... MaltA-te D.
|10|Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. (22700720)
Barbui T.... Tefferi A.
|11|Acral ischemia as a presenting manifestation of essential thrombocythemia. (21858443)
Hanoun M.... Brock F.E.
|12|Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets. (20113333)
Glembotsky A.C.... Heller P.G.
|13|The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. (19887674)
Dragani A.... Rocca B.
|14|The role of the Platelet Function Analyzer (PFA)-100 and platelet aggregometry in the differentiation of essential thrombocythemia from reactive thrombocytosis. (19664802)
Tsantes A.E.... Vaiopoulos G.
|15|Emergence of chronic myelogenous leukemia during treatment for essential thrombocythemia. (20146031)
Mizutani S.... Taniwaki M.
|16|Essential thrombocythemia with deleted 5q--a genetic and morphologic hybrid? (20633767)
Wong K.F.... Wong W.S.
|17|JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients. (19235016)
Palandri F.... Vianelli N.
|18|JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. (19616600)
Hussein K.... Kreipe H.
|19|Comparison of clinicopathologic findings according to JAK2 V617F mutation in patients with essential thrombocythemia. (19093167)
Cho Y.U.... Seo E.J.
|20|JAK2V617F mutation-positive childhood essential thrombocythemia associated with cerebral venous sinus thrombosis. (19707158)
Kurosawa H.... Arisaka O.
|21|Blast phase of essential thrombocythemia: A single center study. (19691103)
Passamonti F.... Lazzarino M.
|22|Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. (19364963)
Campbell P.J.... Green A.R.
|23|Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. (18587010)
Carobbio A.... Barbui T.
|24|Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. (18268279)
De Stefano V.... Barbui T.
|25|Association of inv(3)(q21q26) with essential thrombocythemia in transformation. (18617063)
VillalA^n C.... Ferro M.T.
|26|The V617F JAK2 mutation and the increase in platelet CD36 in essential thrombocythemia are unrelated events. (17573918)
Darghouth D.... Bellucci S.
|27|A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis. (17361221)
Bellosillo B.... Besses C.
|28|Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. (17317589)
Kerbauy D.M.... Deeg H.J.
|29|Pulmonary hypertension in patients with essential thrombocythemia and reactive thrombocytosis. (17852711)
Altintas A.... Ayyildiz O.
|30|Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. (17229651)
Finazzi G.... Barbui T.
|31|Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. (17519959)
Alvarez-LarrA!n A.... Besses C.
|32|Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles. (16563815)
Petrides P.E.... Siegel F.
|33|Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. (16471068)
Wolanskyj A.P.... Tefferi A.
|34|Arterial stenosis and atherothrombotic events in polycythemia vera and essential thrombocythemia. (18386616)
Cucuianu A.... Petrov L.
|35|The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia. (16810614)
Bellucci S.... Michiels J.J.
|36|The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS). (16926301)
Boissinot M.... Hermouet S.
|37|Normal thrombopoietin and its receptor (c-mpl) genes in children with essential thrombocythemia. (15390356)
Randi M.L.... Fabris F.
|38|A critical review of anagrelide therapy in essential thrombocythemia and related disorders. (16019501)
Dingli D.... Tefferi A.
|39|Bone metabolism during interferon-alpha treatment of essential thrombocythemia. (15030122)
Kusec R.... Gisslinger H.
|40|Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia. (15048058)
|41|The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. (13679323)
Ruggeri M.... Rodeghiero F.
|42|Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha-2a and no treatment. A comparative analysis of the literature. (11978937)
Vantroyen B.... Vanstraelen D.
|43|Historical perspective on the treatment of essential thrombocythemia and polycythemia vera. (9930553)
|44|Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia. (9517515)
Lichtman S.M.... Brody J.
|45|Clonality analysis of hematopoiesis and thrombopoietin levels in patients with essential thrombocythemia. (9669688)
El-Kassar N.... Grandchamp B.
|46|A possible role for thrombopoietin and its receptor c-mpl in the pathobiology of essential thrombocythemia. (9387200)
Griesshammer M.... Schrezenmeier H.
|47|Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets. (8978285)
El-Kassar N.... Grandchamp B.
|48|Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. (8883266)
van Genderen P.J.... Michiels J.J.
|49|Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF. (8128427)
Bellucci S.... Boffa M.C.
|50|Essential thrombocythemia developing into refractory anemia and complicated by acute myeloid leukemia. (1286233)
Yonekura S.... Arimori S.